Carlos Schuler, InCarda CEO
June 12, 2023 11:20 AM EDT
R&D

Scoop: In­Car­da ter­mi­nates its PhI­II tri­al for ar­rhyth­mia drug that was cen­tral to plans for an IPO

Kyle LaHucik

Senior Reporter

In­Car­da Ther­a­peu­tics has ter­mi­nat­ed its Phase III tri­al for an in­haled ver­sion of an ir­reg­u­lar heart­beat drug be­cause of “lim­it­ed ef­fi­ca­cy,” ac­cord­ing to a US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times